Mesoblast (ASX:MSB)

Silviu Itescu
CEO & MD
Market Cap (AUD): 1.4B
Sector: Health Care
Last Trade (AUD): 2.1 +0 (+0%)
Tab Bar

1. About

Mesoblast (ASX:MSB) is a world leader in developing innovative cellular medicines. The Company has established what it believes is the industry’s most clinically advanced and diverse portfolio of cell-based product candidates with three programs in Phase 3 clinical studies. Consistent and durable clinical outcomes have been demonstrated across multiple difficult-to-treat diseases. Mesoblast was publically listed on the Australian Securities Exchange in December 2004. The Company has a Level 3 American Depositary Receipt program facility and listed on the Nasdaq (Nasdaq:MESO) in the United States in November 2015.

Its lead product candidates under investigation are:

  • MSC-100-IV for acute graft versus host disease
  • MPC-150-IM for advanced heart failure
  • MPC-06-ID for chronic low back pain due to disc degeneration
  • MPC-300-IV for biologic refractory rheumatoid arthritis and diabetic nephropathy

2. Business model

3. Strategy

4. Markets

5. Competition

6. History

7. Team

8. Financials

9. Risk